GlassScriptPhysician profile
Cameron L Coury
NPI 1104020767
$8,650.98
in general payments reported to CMS, 2019-2025
34 companies · $2,410 in 2025
The $2,410 reported for 2025 was more than what 80% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $715 · 2020: $150 · 2021: $17.48 · 2022: $1,069 · 2023: $1,816 · 2024: $2,474 · 2025: $2,410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,700.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,286.76 | 2019-2025 | Skyrizi, Rinvoq, Botox |
| Genzyme Corporation | $857.91 | 2019-2025 | |
| Lilly USA, LLC | $780.74 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Biotech, INC. | $698.97 | 2019-2025 | Tremfya, Simponi, Stelara |
| Arcutis Biotherapeutics, INC. | $643.58 | 2023-2025 | Zoryve |
| Amgen INC. | $483.03 | 2020-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $470.95 | 2019-2025 | Winlevi |
| Galderma Laboratories, L.P. | $469.78 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Regeneron Healthcare Solutions, INC. | $469.71 | 2019-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $304.67 | 2019-2025 | Adbry, Anzupgo |
| Dermavant Sciences, INC. | $279.02 | 2022-2024 | Vtama |
| Incyte Corporation | $273.66 | 2023-2025 | Opzelura |
| Pfizer INC. | $266.36 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $257.64 | 2019-2025 | |
| Almirall LLC | $206.69 | 2019-2025 | Seysara, Klisyri |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $164.35 | 2019-2025 | Jublia, Cabtreo, Arazlo |
| Mayne Pharma Commercial LLC | $141.83 | 2019-2025 | |
| Ucb, INC. | $78.17 | 2023-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $73.33 | 2023-2025 | Sotyktu |
| Medimetriks Pharmaceuticals, INC. | $59.25 | 2025 | Neo-Synalar, Clindacin Etz |
| Allergan, INC. | $46.59 | 2019-2022 | |
| Dermira, INC. | $42.51 | 2019-2020 | |
| Organon LLC | $42.09 | 2025 | Vtama |
| Journey Medical Corporation | $40.61 | 2022-2025 | |
| Botanix Sb INC | $37.78 | 2025 | Sofdra |
| Vyne Pharmaceuticals INC. | $34.03 | 2020 | |
| Merck Sharp & Dohme LLC | $23.14 | 2019 | |
| Epi Health, LLC | $22.23 | 2022 | |
| Merz North America, INC. | $19.94 | 2022 | |
| Springworks Therapeutics, INC. | $17.98 | 2025 | Gomekli |
| Verrica Pharmaceuticals INC. | $15.85 | 2025 | Ycanth |
| Cipher Pharmaceuticals US LLC | $15.41 | 2025 | Spinosad, Natroba |
| Nabriva Therapeutics, Plc | $13.45 | 2022 | |
| Dusa Pharmaceuticals, INC. | $12.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cameron Coury listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.